| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| RAPT Therapeutics, Inc. | Director | Stock Option (right to buy) | 36,490 | $276,594 | $7.58 | 23 May 2024 | Direct |
| NGM BIOPHARMACEUTICALS INC | Director | Common Stock | 0 | $0 | $1.34 | 05 Apr 2024 | Direct |
| NGM BIOPHARMACEUTICALS INC | Director | Common Stock | 0 | $0 | $1.34 | 05 Apr 2024 | Indirect |
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 130,000 | 15 May 2025 | Direct | ||
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 130,000 | 14 Jun 2024 | Direct | ||
| NGM BIOPHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 0 | 05 Apr 2024 | Direct |